• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.

作者信息

Ding Meijuan, Deng Lili, Yu Ruoying, Lu Dan, Bai Yun, Wu Xue, Shao Yang W, Yang Yu

机构信息

Department of Oncology, the Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China.

Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada.

出版信息

Clin Lung Cancer. 2019 May;20(3):e229-e232. doi: 10.1016/j.cllc.2019.02.014. Epub 2019 Feb 27.

DOI:10.1016/j.cllc.2019.02.014
PMID:30948231
Abstract
摘要

相似文献

1
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.病例报告：基于二代测序的液体活检揭示序贯使用ALK酪氨酸激酶抑制剂治疗的非小细胞肺癌中ALK激活突变的时间异质性
Clin Lung Cancer. 2019 May;20(3):e229-e232. doi: 10.1016/j.cllc.2019.02.014. Epub 2019 Feb 27.
2
Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer.ALK 化合物突变（I1171S + G1269A）克服对多种 ALK 抑制剂的序贯治疗后在非小细胞肺癌中的耐药性。
Thorac Cancer. 2020 Mar;11(3):581-587. doi: 10.1111/1759-7714.13299. Epub 2020 Jan 13.
3
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.布加替尼和劳拉替尼：它们对非小细胞肺癌中 ALK 抑制剂的影响，重点关注耐药突变和中枢神经系统转移。
Jpn J Clin Oncol. 2021 Jan 1;51(1):37-44. doi: 10.1093/jjco/hyaa192.
4
Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.比较 FISH、IHC 和 NGS 检测 ALK 对预测晚期非小细胞肺癌患者接受克唑替尼治疗获益的影响。
Lung Cancer. 2019 May;131:62-68. doi: 10.1016/j.lungcan.2019.03.018. Epub 2019 Mar 20.
5
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.miR-100-5p 赋予 EML4-ALK 阳性 NSCLC 对 ALK 酪氨酸激酶抑制剂克唑替尼和洛拉替尼的耐药性。
Biochem Biophys Res Commun. 2019 Apr 2;511(2):260-265. doi: 10.1016/j.bbrc.2019.02.016. Epub 2019 Feb 18.
6
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.日本间变性淋巴瘤激酶阳性非小细胞肺癌的耐药机制及基于耐药机制的临床反应。
Cancer Sci. 2020 Mar;111(3):932-939. doi: 10.1111/cas.14314. Epub 2020 Feb 8.
7
Brigatinib versus crizotinib for ALK-positive NSCLC.布加替尼与克唑替尼治疗ALK阳性非小细胞肺癌的对比
Lancet Oncol. 2018 Nov;19(11):e585. doi: 10.1016/S1470-2045(18)30741-1. Epub 2018 Oct 4.
8
Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.克唑替尼治疗期间晚期间变性淋巴瘤激酶重排非小细胞肺癌患者中枢神经系统转移的管理。
Clin Lung Cancer. 2019 Nov;20(6):e631-e637. doi: 10.1016/j.cllc.2019.06.013. Epub 2019 Jun 18.
9
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.ALK 阳性晚期非小细胞肺癌对克唑替尼的异质性反应和耐药机制。
Thorac Cancer. 2018 Sep;9(9):1093-1103. doi: 10.1111/1759-7714.12791. Epub 2018 Jul 6.
10
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.晚期间变性淋巴瘤激酶阳性非小细胞肺癌中洛拉替尼的耐药突变与疗效。
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.

引用本文的文献

1
Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.液体活检在癌症免疫治疗中的诊断、监测和预后。
Methods Mol Biol. 2023;2695:127-143. doi: 10.1007/978-1-0716-3346-5_9.
2
Acquired Resistance Mutations Identified from Liquid Biopsy in an -Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report.在接受序贯ALK酪氨酸激酶抑制剂（TKI）治疗的ALK重排鳞状细胞肺癌患者中，通过液体活检鉴定出的获得性耐药突变：一例报告
Onco Targets Ther. 2021 Aug 3;14:4329-4333. doi: 10.2147/OTT.S315832. eCollection 2021.
3
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers.
用于检测非小细胞肺癌耐药机制的液体活检：不同血液生物标志物的比较
J Clin Med. 2019 Jul 9;8(7):998. doi: 10.3390/jcm8070998.